Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.
Clinical trial data on both Eli Lilly's donanemab and leqembi, a highly anticipated drug from Biogen and Japanese drugmaker, indicate they reduce a protein called amyloid. The protein builds up on the brain in Alzheimer's patients and disrupts cell function.
But he said Eli Lilly's decision to stop dosing the drug after it clears a certain amount of amyloid plaque in a patient may not be the best approach to treating the disease. Eli Lilly has not announced similar maintenance dosing plans for donanemab. The company plans to unveil data from a phase three trial on donanemab during the second quarter this year.
Biogen is banking on the success of its drug leqembi after the disastrous approval and rollout of its old Alzheimer's drug aduhelm last year.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eli Lilly to sell low blood sugar drug to Amphastar for around $1 billionAmphastar Pharmaceuticals will buy Baqsimi from Eli Lilly and Co in a deal worth up to $1.08 billion as it aims to boost its portfolio of low blood sugar drugs, the two companies said on Monday.
Lire la suite »
Biogen tops estimates as revenue slides 3% from a year agoBiogen Inc. said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter, up from $303.8 million, or $2.06 a share, in the...
Lire la suite »
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the diseaseThe FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits.
Lire la suite »
Eli Lilly to sell hypoglycemia treatment for up to $1.1 billion in cash and milestone payments to AmphastarShares of Eli Lilly & Co. gained 0.5% in premarket trading Monday, after the drugmaker announced an agreement to sell its hypoglycemia treatment for people...
Lire la suite »
Coca-Cola stock rises on forecast-beating results; Bed Bath & Beyond shares slump and other stocks on the moveCoca-Cola, Bed Bath & Beyond, Foghorn Therapeutics and Eli Lilly are among the biggest moving stocks on Monday.
Lire la suite »